Cardiac complications in cancer treatment - A review

Hellenic J Cardiol. 2017 May-Jun;58(3):190-193. doi: 10.1016/j.hjc.2016.12.003. Epub 2016 Dec 20.

Abstract

Cardiac dysfunction is often associated with effective cancer treatment. A number of targeted therapies against cancer have been observed to cause cardiac dysfunction. In some instances, a patient may outlive his or her cancer but die due to heart failure. Recent research has been focused on the development of new avenues and technological advancements to monitor clinical cardiotoxicity and cardiac dysfunction due to anticancer treatment. These newer treatment options are also increasingly effective and are focused more on post-cancer life. The present review article expands the current view of cardiac complications involved in cancer treatment along with the recent developments in the area.

Keywords: Cancer; Cardiotoxicity; Heart failure; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Cardiotoxicity / complications*
  • Cardiotoxicity / pathology
  • Cardiotoxicity / therapy
  • Cardiotoxins / classification
  • Cardiotoxins / toxicity
  • Heart Diseases / chemically induced*
  • Heart Diseases / epidemiology
  • Heart Diseases / etiology
  • Heart Diseases / physiopathology
  • Heart Failure / chemically induced*
  • Heart Failure / epidemiology
  • Heart Failure / mortality
  • Humans
  • Molecular Targeted Therapy / adverse effects
  • Neoplasms / complications*
  • Neoplasms / drug therapy

Substances

  • Antineoplastic Agents
  • Cardiotoxins